SCHEMBL872211

SCHEMBL872211

COc1ccc(-c2cnc[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.64
CYP3A4 P08684 3/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2D6 P10635 1/20 0.63
IDO1 P14902 2/20 0.58
ASIC3 Q9UHC3 2/20 0.58
POLB P06746 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
MAPT P10636 2/20 0.50
CYP17A1 P05093 1/20 0.50
SCN4A P35499 1/20 0.50
DYRK1A Q13627 1/20 0.50
HRH3 Q9Y5N1 1/20 0.49
NPC1 O15118 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17800997 0.81 IDO1 (0.75) LTA4HCYP3A4CYP1A2CYP2D6IDO1
SCHEMBL871045 0.79 IDO1 (0.58) LTA4HCYP3A4CYP1A2CYP2D6IDO1
SCHEMBL872238 0.78 IDO1 (0.64) LTA4HCYP3A4CYP1A2CYP2D6IDO1
SCHEMBL14129973 0.78 CYP2D6 (1.00) LTA4HCYP3A4CYP1A2CYP2D6ASIC3
SCHEMBL28238890 0.77 CYP17A1 (0.52) CYP3A4IDO1ASIC3POLBSMN1; SMN2
SCHEMBL13030725 0.77 POLB (0.79) LTA4HCYP3A4CYP1A2CYP2D6IDO1
SCHEMBL29578589 0.77 CYP17A1 (0.52) CYP3A4IDO1ASIC3POLBSMN1; SMN2
SCHEMBL30590469 0.77 LTA4H (0.58) LTA4HCYP3A4CYP1A2CYP2D6IDO1
SCHEMBL27880327 0.75 IDO1 (0.67) LTA4HCYP3A4CYP1A2CYP2D6IDO1
SCHEMBL30026881 0.74 IDO1 (0.47) CYP3A4CYP1A2CYP2D6IDO1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2025-03-13 US disclosed
US-12091397-B2 Dihydroquinolinones for medical treatment C4 THERAPEUTICS, INC. 2024-09-17 US disclosed
CN-111278816-B Dihydro quinolinones C4医药公司 2024-03-15 CN disclosed
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2023-06-22 US disclosed
US-11401256-B2 Dihydroquinolinones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-08-02 US disclosed
EP-3679028-A1 DIHYDROQUINOLINONES C4 Therapeutics, Inc. (US) 2020-07-15 EP disclosed
US-20200207733-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
CN-111278816-A Dihydroquinolinones C4医药公司 2020-06-12 CN disclosed
EP-3032625-B1 FUEL CELL SEPARATOR NISSHINBO CHEMICAL INC (JP) 2020-01-08 EP disclosed
WO-2019043208-A1 DIHYDROQUINOLINONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 WO disclosed
EP-2458667-B1 FUEL CELL SEPARATOR NISSHINBO CHEMICAL INC (JP) 2017-05-24 EP disclosed
EP-2763223-B1 POROUS SEPARATOR FOR FUEL CELLS NISSHINBO CHEMICAL INC (JP) 2016-11-16 EP disclosed
EP-3032625-A1 FUEL CELL SEPARATOR Nisshinbo Chemical Inc. (JP) 2016-06-15 EP disclosed
US-20160156044-A1 FUEL CELL SEPARATOR NISSHINBO CHEMICAL INC. (JP) 2016-06-02 US disclosed
EP-2763223-A1 POROUS SEPARATOR FOR FUEL CELLS Nisshinbo Chemical Inc. (JP) 2014-08-06 EP disclosed
US-8372192-B2 Fuel cell separator NISSHINBO CHEMICAL INC. (JP) 2013-02-12 US disclosed
EP-2458667-A1 FUEL CELL SEPARATOR Nisshinbo Chemical Inc. (JP) 2012-05-30 EP disclosed
US-8182975-B2 Positive resist composition and pattern forming method using the same FUJIFILM CORPORATION (JP) 2012-05-22 US disclosed
US-20120077111-A1 FUEL CELL SEPARATOR NISSHINBO CHEMICAL INC. (JP) 2012-03-29 US disclosed
US-20080248419-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091397-B2 Dihydroquinolinones for medical treatment CRBN, RBX1, ADRM1 LTA4H 4221/4885CYP3A4 4686/4885CYP1A2 4657/4885
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 LTA4H 4221/4885CYP3A4 4686/4885CYP1A2 4657/4885
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 LTA4H 4221/4885CYP3A4 4686/4885CYP1A2 4657/4885
US-20200207733-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 LTA4H 4221/4885CYP3A4 4686/4885CYP1A2 4657/4885
US-11401256-B2 Dihydroquinolinones for medical treatment CRBN, RBX1, ADRM1 LTA4H 4221/4885CYP3A4 4686/4885CYP1A2 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.